Table 1. Baseline characteristics of 3,700 Korean patients who underwent first-line H. pylori eradication therapy.

Parameters	Total participants with first-line therapy (n = 3,700) No. (%)	Eradication success (n = 2,701) No. (%)	P value
Age in years			0.001
< 30	144 (3.89)	105 (72.92)
30-39	322 (8.70)	251 (77.95)
40-49	666 (18.0)	511 (76.73)
50-59	1,247 (33.7)	917 (73.54)
60-69	884 (23.89)	625 (70.7)
≥ 70	437 (11.81)	292 (66.82)
Sex			0.328
Male	2,233 (60.35)	1,643 (73.58)
Female	1,467 (39.65)	1,058 (72.12)
Residence			< 0.001
Seoul	809 (21.86)	592 (73.18)
Gyeonggi	692 (18.7)	496 (71.68)
Gangwon	93 (2.51)	68 (73.12)
Chungcheong	310 (8.38)	187 (60.32)
Gyeongsang	1,162 (31.41)	884 (76.08)
Jeolla	276 (7.46)	201 (72.83)
Jeju	358 (9.68)	273 (76.26)
Current smoking			0.799
No	2,045 (67.6)	1,486 (72.67)
Yes	795 (26.28)	568 (71.45)
Alcohol consumption			0.261
No	1,637 (54.12)	1,165 (71.17)
Yes	1,209 (39.97)	894 (73.95)
Medication			0.019
No	1,759 (59.09)	1,285 (73.05)
Yes	1,114 (37.42)	781 (70.11)
Aspirin	215 (19.30)	155 (72.09)
Non-steroidal anti-inflammatory drugs	82 (7.36)	46 (59.76)
Antiplatelet/anticoagulation agents, or steroids	41 (3.68)	28 (68.29)
Previous GI disorder			0.018
No	2,315 (77.27)	1,697 (73.3)
Yes	567 (18.93)	382 (67.37)
Peptic ulcer	417 (73.54)	276 (66.19)
Others	242 (42.68)	158 (65.29)
Comorbidity			0.031
No	1,743 (58.39)	1,289 (73.95)
Yes	1,162 (38.93)	808 (69.54)
Hypertension	721 (62.05)	517 (71.71)
Diabetes	315 (27.11)	227 (72.06)
Ischemic heart disease	62 (5.34)	41 (66.13)
Liver cirrhosis	17 (1.46)	8 (47.06)
Chronic renal failure	17 (1.46)	9 (52.94)
Malignancy	43 (3.70)	28 (65.12)
Others	422 (36.32)	277 (65.64)